The authors present four subtypes of breast cancer, luminal A, luminal B, human epidermal growth factor receptor 2 positive (HER2+), or triple negative (TNBC), of which luminal tumours are the most prevalent, accounting for 60–73% of all recorded cases, with luminal B breast cancer as the most aggressive. Here, ERBB2 is linked to breast cancer.